Day: November 9, 2023

CALGARY, Alberta, Nov. 09, 2023 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) is pleased to report its financial and operating results for the three and nine months ended September 30, 2023. Dollar amounts are expressed in United States dollars, with the exception of Canadian dollar unit prices (“C$”) where indicated and otherwise noted. Highlights for the three and nine months ended September 30, 2023Adjusted EBITDAX increased 11% and 14% to $62.1 million and $183.7 million for the three and nine months ended September 30, 2023, respectively, compared to $56 million and $160.8 million for the same periods in 2022, respectively. The Corporation’s natural gas and LNG operating netback increased 11% and 10% to $4.14 per Mcf and $4.03 per Mcf, for the three and nine months...

Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (zedenoleucel) for the treatment of patients with Acute Myeloid Leukemia (AML) Demonstrated enhanced anti-tumor activity in an aggressive, treatment-resistant AML cell line and provided an update on clinical readiness of the MT-401 Off-the-Shelf (OTS) program HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results...

CALGARY, Alberta, Nov. 09, 2023 (GLOBE NEWSWIRE) — Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three and nine months ended September 30, 2023. Financial Highlights ($000’s except per share data)  Three months endedSeptember 30   Nine months endedSeptember 30  2023 2022 Change   2023 2022 ChangeRevenue $ 232,016 $ 207,678 12 %   $ 678,638 $ 548,334 24 %Operating income   23,691   21,622 10 %     61,112   33,738 81 %EBITDA(1)   44,955   42,335 6 %     123,685   95,448 30 %Cashflow   40,784   41,078 (1 %)     118,864   92,205 29 %Net income   19,237   17,163 12 %     49,455   25,735 92 %Attributable to shareholders   19,231   17,179 12 %     49,472   25,764 92 %                       Per Share Data (Diluted)                      EBITDA(1) $ 1.10 $ 0.98 12 %   $ 3.00 $ 2.21 36 %Cashflow $ 1.00 $ 0.95 5 %   $ 2.88 $ 2.14 35 %                       Attributable...

Company to Host Conference Call at 8:30 AM ET on Friday, November 10, 2023 TROY, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (compared to the prior year period)Gross written premium increased 16.5% to $38.5 million Net investment income increased 68.6% to $1.5 million Expense ratio improved to 33.9%, down 600 bps from the prior year Combined ratio of 120.8%; accident year combined ratio excluding the impact of storm-related losses was 95.3% (6)Management Comments James Petcoff, Executive Chairman and Co-CEO, commented, “While the third quarter results were affected by atypically severe storm losses, it is important to emphasize that our growing core lines...

VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) — Tree Island Steel (”Tree Island” or the ”Company”) (TSX: TSL) announced today its financial results for the nine months ended September 30, 2023. For the three-month period ended September 30, 2023, revenues decreased by $26.8 million to $53.4 million from $80.2 million in the same period in 2022. The reduction was the result of declines in steel prices in the quarter influencing market prices for our products, current market headwinds, and lower shipped volume from the previously announced closure of our Etiwanda facility. Gross profit for the third quarter decreased to $6.0 million, from $14.6 million in the same period in 2022, for the same reasons. Adjusted EBITDA amounted to $4.1 million, compared to $12.2 million during the same period in...

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates. Third Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable securities were $228.7 million as of September 30, 2023, compared to cash, cash equivalents and marketable securities of $251.7 million as of December 31, 2022. Cash equivalents and other financial assets comprise money market funds. Marketable securities comprise investment grade bonds. We believe that our existing cash, cash equivalents, other financial assets and marketable securities will be sufficient...

SUGAR LAND, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights1:Reported total revenues of $206.7 million. Grew gross margin to 25.5% of revenue or $52.8 million. Decreased net loss from continuing operations to $12.1 million, a 54.4% improvement over the 2022 third quarter net loss from continuing operations of $26.6 million. Grew consolidated Adjusted EBITDA2 to $11.1 million (5.4% of consolidated revenue), up from $10.6 million (4.9% of consolidated revenue) in the 2022 third...

HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG) (“Koil Energy” or the “Company”), a specialist in deepwater production and distribution equipment and services, today reported results for the quarter ended September 30, 2023. Koil Energy at a Glance:Share Price†: $0.45 Cash*:       $1.1M52-Week Range†: $0.42 – $0.72 Book Value*: $6.5MShares Out.†: 11.9M Price / Book Value: 0.8xMarket Cap†: $5.4M TTM Revenue: $15.0M*As of 09/30/23; †As of 11/08/23      Charles Njuguna, Koil Energy’s CEO, commented, “While our earnings for the third quarter didn’t live up to our expectations, we are encouraged by our increased revenues for the quarter. Compared to the same quarter a year ago, revenues increased by 82% and were driven by sustained growth in service projects and our expanding...

GEORGE TOWN, Cayman Islands, Nov. 09, 2023 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading developer and operator of advanced water supply and treatment plants, reported results for the third quarter ended September 30, 2023. All comparisons are to the same prior year period unless otherwise noted. The company will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). Third Quarter 2023 Financial HighlightsTotal revenue increased 99% to $49.9 million. Retail revenue increased 15% to $7.2 million. Services revenue increased 237% to $29.4 million, with recurring services revenue generated from operations and maintenance contracts up 48% to $5.0 million. Manufacturing revenue increased to $4.7 million.  Net income from continuing...

ELI-002 2P promising median relapse-free survival of 16.3 months in AMPLIFY-201 Phase 1a study presented at AACR Special Conference: Pancreatic Cancer ELI-002 2P induced T cell responses correlated with an 86% reduction in the risk of progression or death Both CD4+ and CD8+ T Cells targeting mutant KRAS were induced T cell responses to ≥ two mKRAS antigens were observed in 90% of immune responders presented at the Society for Immunotherapy of Cancer Anticipate initiating ELI-002 7P randomized Phase 2 trial in early 2024BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX)(“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2023, and...